Equities

Acumen Pharmaceuticals Inc

ABOS:NSQ

Acumen Pharmaceuticals Inc

Actions
  • Price (USD)2.53
  • Today's Change-0.145 / -5.42%
  • Shares traded182.30k
  • 1 Year change+24.63%
  • Beta0.0105
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments244178194
Total Receivables, Net----0
Total Inventory------
Prepaid expenses2.992.494.28
Other current assets, total0.110.240.14
Total current assets247180199
Property, plant & equipment, net0.500.270.04
Goodwill, net------
Intangibles, net------
Long term investments631632
Note receivable - long term------
Other long term assets0.220.150.01
Total assets310197230
LIABILITIES
Accounts payable1.381.641.09
Accrued expenses116.043.86
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.76----
Other current liabilities, total0.210.130.20
Total current liabilities137.815.15
Total long term debt3000
Total debt3100
Deferred income tax------
Minority interest------
Other liabilities, total0.28--0
Total liabilities437.815.15
SHAREHOLDERS EQUITY
Common stock0.010.000.00
Additional paid-in capital489360353
Retained earnings (accumulated deficit)(223)(170)(128)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.31(0.75)(0.23)
Total equity267189225
Total liabilities & shareholders' equity310197230
Total common shares outstanding584140
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.